Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
Biogen Inc. is at a significant point in its pipeline development, with 10 Phase III programs expected to have clinical readouts starting in the fourth quarter. The company aims to diversify beyond its neurology focus by investing in immunology and nephrology, expanding its portfolio with potential products like felzartamab for kidney transplant rejection and other indications.
This diversification comes following a strategic shift to offset declines in its multiple sclerosis business and return to growth. Biogen anticipates around $250 million in annualized cost savings by next year, as it manages the Apellis acquisition-related interest costs and plans to pay down acquisition debt by the end of 2027.
The company's Fit for Growth initiative focuses on optimizing costs and infrastructure while redirecting investment to newer launches, including LEQEMBI, SKYCLARYS, and ZURZUVAE. Biogen's research priorities now include programs with the highest conviction, and the company has initiated Phase II studies involving CD38 in autoantibody-driven diseases outside nephrology.
Following the Apellis acquisition, Biogen expects dilutive effects in 2026 due to interest expenses but remains bullish on future growth.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
